Dr Reddy’s launches ‘Redispar’ in domestic market; stock soars 3%
Dr Reddy's Laboratories Ltd, an emerging global pharmaceutical company, has finally launched RedisparT (Doxercalci) in Indian market.
According to a press release, RedisparT is the first pro-vitamin D2 to be available in the country, which is used in the treatment of secondary hyperparathyroidism (SHPT) due to chronic kidney disease.
In addition, the drug is also used to maintain the parathyroid hormone (PTH) and calcium levels in the body in chronic kidney disease patients.
The company informed that after considering various clinical research reports, it has been cleared that Doxercalciferol is safer and more effective in comparison to Calctirol (vitamin D3) and Alfacalcidol (pro vitamin D3).
The drug will be available in soft gelatin capsule form, and in dosages of 0.5mcg and 2.5mcg.
Shares of the company closed up Rs 15, or 3%, at Rs 553. The total volume of shares traded at the BSE was 23,990 (Wednesday).